Famotidine is an H2 receptor antagonist indicated for duodenal and gastric ulcers, GERD and pathological hypersecretory conditions. We supply it to US manufacturers of tablets, oral suspension and injection.
Data from PubChem (CID 5702160) and FDA’s substance registry
CAS number
76824-35-6
Molecular formula
C8H15N7O2S3
Molecular weight
337.5g/mol
FDA UNII
IUPAC name
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
InChIKey
XUFQPHANEAPEMJ-UHFFFAOYSA-N
- Appearance
- White to pale yellowish-white crystalline powder.
- Solubility
- Very slightly soluble in water. Freely soluble in dimethylformamide and glacial acetic acid, slightly soluble in methanol, and practically insoluble in acetone and alcohol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Has two polymorphs, A and B. Confirm which form the source supplies and how it controls it.
On the US market
- Reference product
- PepcidNDA 019462
- Approved ANDAs
- 60 with a marketed product
- Approved forms and strengths
- Tablet 10 mg, 20 mg, 40 mg
- Powder for oral suspension 40 mg/5 mL
- Injection 0.4 mg/mL, 10 mg/mL
- Chewable tablet 20 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com